Potiga
Refractory Partial Onset Seizures
Treatment
1 FDA approval
0 Active Studies for Potiga
Treatment for
Refractory Partial Onset Seizures
What is Potiga
Ezogabine
The Generic name of this drug
Treatment Summary
Ezogabine (also known as D23129) is a medication used to treat epilepsy in adults. It works by opening potassium channels in nerve cells and helps reduce the frequency of seizures. It is the first medication of its kind and was approved by the FDA in 2011. Ezogabine is prescribed as an additional treatment for people with partial-onset seizures who have not responded to other medications.
Potiga
is the brand name
Potiga Overview & Background
Brand Name
Generic Name
First FDA Approval
How many FDA approvals?
Potiga
Ezogabine
2012
4
Approved as Treatment by the FDA
Ezogabine, otherwise called Potiga, is approved by the FDA for 1 uses including Refractory Partial Onset Seizures .
Refractory Partial Onset Seizures
Effectiveness
How Potiga Affects Patients
Ezogabine is different than other antiepileptic drugs because it activates certain potassium ion channels that don't lead to cardiac side effects. This drug is used to treat epilepsy and other diseases, and it is known to be very effective. Research has also suggested that ezogabine may be helpful in relieving pain and anxiety. Clinical studies also show that ezogabine is safe, there is no tolerance, dependence, or withdrawal when taken at the right dose. Therefore, ezogabine may be used to treat a variety of illnesses caused by too much neuronal activity.
How Potiga works in the body
Ezogabine helps regulate nerve firing in the brain and stabilizes the electrical activity to reduce seizure activity. It does this by opening special potassium channels that control the M-current, and also by increasing the effects of the GABA neurotransmitter, which helps to calm nerve activity. Numerous studies have shown that ezogabine is effective in reducing seizures.
When to interrupt dosage
The advised measure of Potiga hinges on the acknowledged disorder. The dosage amount can be found in the table below, subject to the method of administration (e.g. Tablet, film coated - Oral or Oral).
Condition
Dosage
Administration
Refractory Partial Onset Seizures
, 100.0 mg, 200.0 mg, 300.0 mg, 400.0 mg, 50.0 mg
, Oral, Tablet, film coated, Tablet, film coated - Oral
Warnings
There are 20 known major drug interactions with Potiga.
Common Potiga Drug Interactions
Drug Name
Risk Level
Description
Azelastine
Major
Ezogabine may increase the central nervous system depressant (CNS depressant) activities of Azelastine.
Hydroxyzine
Major
The risk or severity of QTc prolongation can be increased when Ezogabine is combined with Hydroxyzine.
Mobocertinib
Major
The risk or severity of QTc prolongation can be increased when Ezogabine is combined with Mobocertinib.
Oliceridine
Major
The risk or severity of hypotension, sedation, death, somnolence, and respiratory depression can be increased when Ezogabine is combined with Oliceridine.
Thalidomide
Major
Ezogabine may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.
Potiga Toxicity & Overdose Risk
The lethal dose of Xanax in rats is 100mg/kg. For long-term use, the lethal dose is 5.1mg/kg per day for 90 days. The most common side effects that lead to ceasing treatment with Xanax are dizziness and feeling sleepy.
Potiga Novel Uses: Which Conditions Have a Clinical Trial Featuring Potiga?
At present, there are no active trials examining the potential of Potiga to ameliorate Refractory Partial Onset Seizures.
Condition
Clinical Trials
Trial Phases
Refractory Partial Onset Seizures
0 Actively Recruiting
Potiga Reviews: What are patients saying about Potiga?
5
Patient Review
6/17/2013
Potiga for Simple Seizure
4
Patient Review
10/23/2013
Potiga for Simple Seizure
2
Patient Review
6/2/2014
Potiga for Simple Seizure
2
Patient Review
1/20/2013
Potiga for Simple Seizure
Patient Q&A Section about potiga
These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Is ezogabine a controlled substance?
"Ezogabine will be classified as a Schedule IV drug under the Controlled Substances Act, due to the potential for abuse leading to physical or psychological dependence."
Answered by AI
Why was potiga discontinued?
"remove
The company has stated that the withdrawal is for commercial reasons due to limited use of the drug and declining numbers of patients who start therapy with the drug."
Answered by AI
What kind of drug is potiga?
"Potiga is a drug used to treat partial onset seizures. It may be used alone or with other medications. Potiga belongs to a class of drugs called anticonvulsants or neuronal potassium channel openers."
Answered by AI
Why was retigabine withdrawn?
"This product is no longer being manufactured because it is not being used as often and the demand for it is declining. The letter from the company says that healthcare providers should start seeking other options for treatment for patients who are currently taking this product and to do so gradually over the course of at least 3 weeks by reducing the dose. New patients should not start taking this product."
Answered by AI